Mechanism
Autologous adoptive cell therapy
Assets acting on this target.
- Class
- Autologous adoptive cell therapy — bone-marrow-derived, ex-vivo-expanded, activated polyclonal tumor-specific T lymphocytes (Marrow Infiltrating Lymphocytes, MILs™)
- Pathway
- expands a polyclonal population of pre-existing tumor-reactive T cells from a patient's own bone marrow rather than engineering a single-antigen receptor, then reinfuses them, often combined with a checkpoint inhibitor (pembrolizumab/nivolumab)
- Notes
- original target text: Autologous adoptive cell therapy — bone-marrow-derived, ex-vivo-expanded, activated polyclonal tumor-specific T lymphocytes (Marrow Infiltrating Lymphocytes, MILs™)
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.